SLAM
PCRX icon

Swiss Life Asset Management’s Pacira BioSciences PCRX Stock Holding History

Swiss Life Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,968
Closed -$206K – 1585
2025
Q4 		$206K Buy
+7,968
New +$189K ﹤0.01% 1266

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Swiss Life Asset Management's PCRX Position: Q1 2026 in Review

Swiss Life Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 7,968 shares — an estimated $206K sold.

Swiss Life Asset Management first reported a position in PCRX in Q4 2025 and held it in 1 quarter. The position peaked at $206K in Q4 2025. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Swiss Life Asset Management reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
  • Swiss Life Asset Management sold 7,968 Pacira BioSciences shares in Q1 2026, an estimated $206K.
  • Swiss Life Asset Management first reported a position in Pacira BioSciences in Q4 2025 and held it in 1 quarter.
  • Swiss Life Asset Management's Pacira BioSciences position peaked at $206K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Swiss Life Asset Management's 13F filing for Q1 2026, filed 14 May 2026.